FyMed Demonstrates Superiority of FY101C over Ibuprofen and Naproxen…

   July 20, 2012    Comments Off on FyMed Demonstrates Superiority of FY101C over Ibuprofen and Naproxen…    Posted in: General Biotechnology

FyMed, Inc. today announced results from comparative in-vivo studies of FY101C, its lead NSAID candidate, which demonstrated significant superiority to conventional NSAIDs in terms of efficacy and...

(PRWeb July 20, 2012)

Read the full story at http://www.prweb.com/releases/2012/7/prweb9719272.htm

  

Comments are closed.

Biotechblog